Effect of MN-166 (ibudilast) on acute respiratory failure prevention in hospitalized participants with COVID-19: a randomized, double-blind, placebo-controlled phase 2 study

MN-166 (ibudilast) is an orally available small molecule drug candidate that inhibits macrophage migration inhibitory factor and phosphodiesterase 4 and 10. The rationale for using MN-166 to prevent Acute Respiratory Failure (ARF) is based upon its cellular and molecular target actions and recent research in LPS-induced ARF animal model. In this double-blind, randomized (1:1), placebo-controlled study conducted at two centers in the United States, we evaluated MN-166 (100 mg/day: 50 mg twice daily for 7 days) compared to placebo in hospitalized participants with COVID-19 at risk for ARF. The study’s co-primary endpoints were the proportion of participants free of respiratory failure at Day 7 and the proportion of participants with at least a one-point clinical status improvement in the National Institute of Allergy and Infectious Diseases 8-point ordinal scale at Day 7. All randomized participants received a study drug and were evaluated for efficacy and safety. A total of 34 participants were randomly assigned to either MN-166 or placebo (17 in each treatment group). The study achieved one of the co-primary endpoints, a statistically significant difference (P < 0.02) between groups related to the proportion of participants free from respiratory failure. Two-fold of participants in the MN-166 treatment group were free from respiratory failure on Day 7 versus the placebo group (70.6% vs. 35.3%; percentage difference: 35.3% [95% CI: 1.98 to 59.46]; P < 0.02). Sensitivity analysis showed similar differences among participants receiving interleukin-6 antibody therapy, with a statistically significant percentage difference from the placebo group (71.4% vs. 25%; 46.4%, 95% CI: 1.48 to 91.38, P < 0.05). MN 166 treatment was better tolerated than placebo. Two deaths were reported in the placebo group and none in the MN-166 treatment group. MN-166 treatment was associated with faster recovery from respiratory failure in participants with COVID-19, independent of interleukin-6 antibody therapy. MN-166 was well-tolerated with fewer adverse events compared to placebo. ClinicalTrials.gov NCT04429555, Registered 11 June 2020,

Authors

Institutions

Publication Details

Journal
BMC Pulmonary Medicine
Published
2026-04-02
DOI
https://doi.org/10.1186/s12890-026-04261-8
Primary Topic
Macrophage Migration Inhibitory Factor
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of MN-166 (ibudilast) on acute respiratory failure prevention in hospitalized participants with COVID-19: a randomized, double-blind, placebo-controlled phase 2 study

Emelia Klonowski, David Wyles, Yuichi Iwaki, Kazuko Matsuda
BMC Pulmonary Medicine
Macrophage Migration Inhibitory Factor
article

Effect of MN-166 (ibudilast) on acute respiratory failure prevention in hospitalized participants with COVID-19: a randomized, double-blind, placebo-controlled phase 2 study

Emelia Klonowski, David Wyles, Yuichi Iwaki, Kazuko Matsuda
article en

Abstract

MN-166 (ibudilast) is an orally available small molecule drug candidate that inhibits macrophage migration inhibitory factor and phosphodiesterase 4 and 10. The rationale for using MN-166 to prevent Acute Respiratory Failure (ARF) is based upon its cellular and molecular target actions and recent research in LPS-induced ARF animal model. In this double-blind, randomized (1:1), placebo-controlled study conducted at two centers in the United States, we evaluated MN-166 (100 mg/day: 50 mg twice daily for 7 days) compared to placebo in hospitalized participants with COVID-19 at risk for ARF. The study’s co-primary endpoints were the proportion of participants free of respiratory failure at Day 7 and the proportion of participants with at least a one-point clinical status improvement in the National Institute of Allergy and Infectious Diseases 8-point ordinal scale at Day 7. All randomized participants received a study drug and were evaluated for efficacy and safety. A total of 34 participants were randomly assigned to either MN-166 or placebo (17 in each treatment group). The study achieved one of the co-primary endpoints, a statistically significant difference (P < 0.02) between groups related to the proportion of participants free from respiratory failure. Two-fold of participants in the MN-166 treatment group were free from respiratory failure on Day 7 versus the placebo group (70.6% vs. 35.3%; percentage difference: 35.3% [95% CI: 1.98 to 59.46]; P < 0.02). Sensitivity analysis showed similar differences among participants receiving interleukin-6 antibody therapy, with a statistically significant percentage difference from the placebo group (71.4% vs. 25%; 46.4%, 95% CI: 1.48 to 91.38, P < 0.05). MN 166 treatment was better tolerated than placebo. Two deaths were reported in the placebo group and none in the MN-166 treatment group. MN-166 treatment was associated with faster recovery from respiratory failure in participants with COVID-19, independent of interleukin-6 antibody therapy. MN-166 was well-tolerated with fewer adverse events compared to placebo. ClinicalTrials.gov NCT04429555, Registered 11 June 2020,

BMC Pulmonary Medicine
Denver Health Medical Center (US), MediciNova (United States) (US), University of Colorado Denver (US)
Good health and well-being
Openalex Percentile: Top 8%
Macrophage Migration Inhibitory Factor
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.